Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan: a case report

ABSTRACT: Abstract

Background

Cancer therapy–related cardiac dysfunction (CTRCD) is a challenging and life-threatening complication of many chemotherapeutic regimens. CTRCD prevention, diagnosis, and therapy require both careful interdisciplinary assessment and management. For patients with CTRCD, current guidelines of the European Society of Cardiology (ESC) recommend an angiotensin-converting-enzyme inhibitor in combination with a beta-blocker. Recent studies indicate a beneficial effect of sacubitril/valsartan in this patient population.

Case summary

A 68-year-old female patient with a pleural epithelioid angiosarcoma developed heart failure with reduced ejection fraction and elevated serum biomarkers following doxorubicin treatment. After implementation of a recommended cardiop

SUBMITTER:  

PROVIDER: S-EPMC9575188 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature